Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alnylam Pharmaceut (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,031,885
  • Shares Outstanding, K 101,030
  • Annual Sales, $ -550,060 K
  • Annual Income, $ 60,090 K
  • 36-Month Beta 2.54
  • Price/Sales 86.29
  • Price/Cash Flow N/A
  • Price/Book 5.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -2.28
  • Number of Estimates 5
  • High Estimate -1.99
  • Low Estimate -2.54
  • Prior Year -1.48
  • Growth Rate Est. (year over year) -54.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.57 +18.56%
on 11/15/18
85.55 -11.90%
on 12/04/18
+8.06 (+11.97%)
since 11/13/18
3-Month
63.57 +18.56%
on 11/15/18
99.07 -23.92%
on 09/14/18
-19.59 (-20.63%)
since 09/13/18
52-Week
63.57 +18.56%
on 11/15/18
153.99 -51.05%
on 03/20/18
-49.49 (-39.64%)
since 12/13/17

Most Recent Stories

More News
Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Array BioPharma

NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working...

ALNY : 75.73 (-4.74%)
5 Top Drug/Biotech Merger & Acquisition Targets for 2019

Here are five stocks that are attractive and most likely to be takeout targets in 2019.

CELG : 69.46 (-2.03%)
BMRN : 93.53 (-1.04%)
VRTX : 172.50 (-1.68%)
ALNY : 75.73 (-4.74%)
INCY : 67.51 (-0.24%)
SNY : 44.74 (-0.91%)
ALXN : 113.41 (-3.08%)
Alnylam Announces Settlement of Litigation with Silence Therapeutics

Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has resolved all litigation worldwide with Silence Therapeutics. The settlement...

ALNY : 75.73 (-4.74%)
SLNCF : 0.7240 (-15.32%)
Why Is Alnylam (ALNY) Up 9.2% Since Last Earnings Report?

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALNY : 75.73 (-4.74%)
Recent Analysis Shows Microsoft, Alnylam Pharmaceuticals, F5 Networks, Green Plains Partners LP, Itron, and Progress Software Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Microsoft Corporation (NASDAQ:MSFT),...

MSFT : 109.20 (+0.11%)
ITRI : 52.12 (-1.77%)
GPP : 14.36 (-0.28%)
ALNY : 75.73 (-4.74%)
PRGS : 35.34 (-0.06%)
FFIV : 169.37 (-0.58%)
Alnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day

--a^' Initiates Rolling Submission of Givosiran NDA to U.S. Food and Drug Administration (FDA) -

ALNY : 75.73 (-4.74%)
Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sage Therapeutics

NEW YORK, NY / ACCESSWIRE / November 30, 2018 / U.S. markets closed lower on Thursday as investors await details from this weekend's trade meeting between President Trump and Chinese President Xi Jinping....

ALNY : 75.73 (-4.74%)
Sage Therapeutic has the Best Relative Performance in the Biotechnology Industry (SAGE , ALNY , BLUE , SGEN , VNDA )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

BLUE : 101.16 (-6.10%)
ALNY : 75.73 (-4.74%)
SAGE : 102.54 (-7.33%)
After Yesterday's Rally of 2.47% Shares Could Potentially Pullback

Alnylam Pharmace (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $77.73 to a high of $80.99. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high...

ALNY : 75.73 (-4.74%)
Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate

Alnylam (ALNY) and Vir commence phase I/II study for VIR-2218 for the treatment of chronic HBV infection.

MRK : 78.63 (+0.79%)
ALNY : 75.73 (-4.74%)
GILD : 67.18 (-1.41%)
BMY : 53.64 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ALNY with:

Business Summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies,...

See More

Key Turning Points

2nd Resistance Point 82.74
1st Resistance Point 81.12
Last Price 75.73
1st Support Level 77.79
2nd Support Level 76.09

See More

52-Week High 153.99
Fibonacci 61.8% 119.45
Fibonacci 50% 108.78
Fibonacci 38.2% 98.11
Last Price 75.73
52-Week Low 63.57

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar